The University of Michigan, the University of Illinois and the Penn State Research Foundation have presented rifamycin derivatives acting as RNA polymerase (bacterial) inhibitors reported to be useful for the treatment of tuberculosis.
The Project to Accelerate New Treatments for Tuberculosis is progressing two investigational tuberculosis combination treatment regimens into phase II trials under a joint development agreement.
It’s been a patchy year for vaccine specialist Valneva SE, in which it saw European orders for its delayed
COVID-19 vaccine dry up but then received a €90.5 million (US$92.1 million) investment from Pfizer Inc. as its Lyme disease vaccine entered phase III. The firm has now hit another setback after the U.S. Department of Defense decided not to take an option for a second year in contract to supply a Japanese encephalitis vaccine, Ixiaro.
Staphylococcus aureus is the most common bacterium recovered in orthopedic infections. Exebacase and CF-296 (ContraFect) are known to be anti-staphylococcal lysins with activity against S. aureus.
Blue Water Vaccines Inc. is ready to try its hand at developing a monkeypox vaccine. The company is launching an exploratory program to develop a vaccine attempting to present antigens within its norovirus shell and protrusion virus-like particle (VLP) platform.
Researchers from Bioland Laboratory (Guangzhou Regenerative Medicine and Health - Guangdong Laboratory) and the University of Groningen have generated a series of novel biphenyl-benzamides as inhibitors of cell division protein FtsZ with encouraging antibacterial activity.
Orna Therapeutics Inc., which is pioneering a novel circular RNA protein expression technology in several therapeutic areas, has achieved lift-off. The Cambridge, Mass.-based company has closed a broadly based alliance in infectious disease and oncology with Merck & Co. Inc., under which it is getting $150 million up front and up to $3.5 billion in development, regulatory and sales-based milestones. In addition, Merck, of Rahway, N.J., is investing another $100 million in Orna’s equity, as part of its $221 million series B round, which the company also disclosed on Aug. 16.
RSS
